July 29, 2026

How Can Biotechs Optimize Their One-on-One Schedules at Healthcare Investor Conferences?

This blog follows on from our earlier entries: “What Are the Top Investor Conferences for Public U.S. Biotechs?” and “How Many Healthcare Investor Conferences Should a Biotech Attend Each Year?” as well as “How Should Biotechs Think About Shareholder Targeting?”

Healthcare investor conferences are an unavoidable feature of the public biotech calendar. But unlike large-cap pharmaceutical companies – whose meeting schedules are often oversubscribed as soon as conference portals go live – small- and mid-cap biotechs typically are not overwhelmed with such requests.

There are exceptions, of course. A company with fresh positive data, following a high-profile financing, or a “flavor of the month” disease vertical or mechanism of action may find itself fully booked. But for most emerging biotechs, conferences are not about managing excess demand.

That being said, every biotech can benefit from optimizing its one-on-one schedule to make the most of the opportunity presented.

1. Compress your schedule intelligently

Management time is your most valuable asset after your patents. Your CEO, CMO, and CFO should not be sitting in hotel lobbies for three days waiting for scattered one-on-ones to take place.

Whenever possible, compress meetings into the same day as your webcast presentation. Stay multiple days only if you have sufficient high-quality demand to justify it.

If quality investors cannot fit into a single day, offer follow-up calls. A well-scheduled Zoom meeting two weeks later is often more productive than an  in-person meeting squeezed in at 7:30 a.m., when management might not be at their best.

2. Curate your one-on-ones

Not all meetings are created equal. Your conference meeting schedule should reflect strategic prioritization.

Start with investors on your Shareholder Targeting list – the institutions that profile correctly for your stage, indication, and market cap.

Then prioritize high-quality funds on your broader marketing list that you have not seen recently. Conferences are an opportunity to advance new relationships or deepen existing ones.

Avoid spending time with very small funds that cannot realistically take a meaningful position in your cap table. Your IR partner (or platforms such as Ipreo / IR Insight) can help assess position-sizing capacity and historical behavior.

Similarly, hedge funds that met with you in the last 90 days and have not built a position (if this is discernable) should be deprioritized. They may be looking for short-term trading catalysts rather than long-term ownership. That does not make them “bad” investors – but it does make them lower priority relative to potential durable holders.

3. Be thoughtful about group meetings

Group meetings can be efficient – but only if curated properly.

Do not place a brand-new investor in a room with a long-term holder who knows the story intimately. They require different narratives:

• A new investor needs the full strategic arc: platform rationale, differentiation, probability of success, capital runway.
• An existing investor wants incremental insight: updated enrollment timelines, biomarker nuance, competitive positioning shifts.
• Blending the two dilutes the impact for both.

If you must hold group meetings, segment them appropriately.

4. Avoid redundant meetings

Some investors will request meetings at multiple events within the same quarter to preserve optionality for themselves – often these requests are made by an administrative assistant.

There is no reason to meet repeatedly with a fund if the story has not evolved. If there has been no material change since you recently met – politely decline and offer to reconnect when there is new information.

5. Focus on quality, not volume

It is tempting to measure conference success by the number of meetings held. Resist that instinct.

Ten high-quality meetings with funds that can each own 3-5% of your company are more valuable than twenty meetings with investors who will never build a meaningful stake.

Ask yourself:

• Can this investor own in size?
• Do they invest in biotechs at my stage of development?
• Do they represent long-only, durable capital?
• Have they engaged constructively in prior meetings?

If the answers are underwhelming, your time might be better spent elsewhere.

6. Remember the objective

Healthcare conferences are not roadshows. They are not financing events (though they can support future ones). They are relationship-building forums.

Your goals are simple:

• Expand awareness among the right investors.
• Deepen conviction among existing holders.
• Lay the groundwork for future capital raises.
• Increase the probability that, when data hits, the right funds are already familiar with your story.

A well-managed conference strategy compounds over time. A poorly managed one exhausts management without moving the existing and potential shareholder base meaningfully forward.